Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoarthritis
Intervention: Paracetamol 665 mg (Drug); Paracetamol 500 mg (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The aim of this observational study is to compare the use of an extended release paracetamol
formulation with standard paracetamol in a cohort of Australian concessional patients with
osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.
Clinical Details
Official title: Panadol Osteo PBS Claims Cohort Study
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation
Detailed description:
This retrospective analysis of physician prescribing data (long-term concessional cohort
from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will
compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol
500mg in a cohort of Australian concessional patients with OA, to assess differences in
prescribing patterns and patient compliance.
Eligibility
Minimum age: 50 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participants prescribed with a paracetamol product and categorized as a concessional
patient
- Participants with new episodes of OA (no history of OA paracetamol in previous 12
months) or suffering from chronic OA (history of OA paracetamol in the previous 12
months)
Exclusion Criteria:
- Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions
- Participants receiving the following anti-rheumatoid therapies: Immunimodulators such
as methotrexate, leflunamide and TNF blockers
- Participants receiving treatment for cancer pain
Locations and Contacts
Additional Information
Starting date: January 2013
Last updated: December 11, 2014
|